Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Raised to Strong-Buy at Barclays

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was upgraded by analysts at Barclays to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Swedish Orphan Biovitrum AB (publ) Price Performance

Shares of OTCMKTS:BIOVF opened at $28.30 on Wednesday. Swedish Orphan Biovitrum AB has a 1-year low of $22.87 and a 1-year high of $32.25. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49. The stock has a market cap of $10.07 billion, a P/E ratio of 47.97 and a beta of 0.51. The firm has a fifty day moving average price of $28.81 and a 200 day moving average price of $28.35.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.